Presentations and e-publications from SCCA clinicians to feature the latest research on breast, gastrointestinal, genitourinary, lung, renal and sarcoma cancers, and hematological malignancies

SEATTLE–(BUSINESS WIRE)–Seattle Cancer Care Alliance (SCCA), announced today the new findings from its clinicians that will be featured at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program May 29-31, 2020.

SCCA clinicians contributed to discoveries from clinical trials across multiple cancer types, including results from immunotherapy clinical trials. They provided perspectives on the clinical impact of COVID-19 on patients with cancer and on financial issues associated with clinical trials and cancer treatment. They also contributed to new findings related to genetic testing, cardiovascular disease among women with breast cancer and personalized cancer care.

“As the only NCI* and NCCN* designated cancer center in the state of Washington, SCCA was established, in part, to help bring promising new treatments to patients faster,” said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance and a former ASCO president. “The presentations and publications with which our specialists are associated at ASCO demonstrate SCCA’s expertise in cancer diagnosis and treatment, including the clinical impact of COVID-19. They also represent some of the latest findings in clinical research that will enhance patient care today and into the future.”

More information about SCCA’s presentations and publications at ASCO is available at https://www.seattlecca.org/asco.

Oral Presentations

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis
Abstract: LBA1

SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology

EMBARGO: Thursday, May 28, 5:00 p.m. ET

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)
Abstract: LBA110

SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology

EMBARGO: Thursday, May 28, 5:00 p.m. ET

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA)
Abstract: 4504

SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab in combination with durvalumab for patients with advanced hepatocellular carcinoma
Abstract: 4508

SCCA author: William P. Harris, MD

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)
Abstract: 5000

SCCA author: Petros Grivas, MD, PhD, Clinical Director Genitourinary Medical Oncology

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)
Abstract: 5007

SCCA author: Scott Tykodi, MD, PhD

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC)
Abstract: 500

SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416)
Abstract: 1001

SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded)
Abstract: 1002

SCCA Author: Shaveta Vinayak, MD, MS

Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC)
Abstract: 5007

SCCA Author: Scott Tykodi, MD

Poster Presentations

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial
Abstract: 4618

SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC-MRD Consortia)
Abstract: 4108

SCCA author: Stacey Cohen, MD

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
Abstract: TPS4671

SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer
Abstract: 4018

SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD
Abstract: 7010

SCCA author: Veena Shankaran, MD, MS

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)
Abstract: 4582

SCCA author: David Zhen, MD

Cost implications of clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC)
Abstract: 7084

SCCA authors: Keith Eaton, MD, PhD, Service Medical Director, Bernardo Goulart, MD, and Renato Martins, MD, MPH, Clinical Director, Thoracic, Head and Neck Oncology

Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA Prostate Oncology Clinic
Abstract: 1578

SCCA authors: Heather Cheng, MD, PhD, Director, Prostate Cancer Genetics Clinic, and Robert Montgomery, MD

Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427
Abstract: 5024

SCCA author: Scott Tykodi, MD, PhD

Title: Relation between measurable residual disease and morphologic relapse in AML
Abstract: 7535

SCCA author: Lauren Shih, MD

A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer
Abstract: TPS1103

SCCA Author: William Gwin, MD

Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105)
Abstract: 12019

SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study
Abstract: 12016

SCCA Author: Heather Greenlee, ND, PhD, Director, Integrative Medicine Program

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)
Abstract: 1043

SCCA Author: Jennifer Specht, MD

A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer
Abstract: TPS 1104

SCCA Author: Jennifer Specht, MD

Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care on the ground
Abstract: 2011

SCCA Author: Benjamin Anderson, MD

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
Abstract: 4671

SCCA Author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A
Abstract: 5069

SCCA Author: Scott Tykodi, MD

Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
Abstract: 1070

SCCA Author: Hannah Linden, MD

Gender differences in faculty rank and subspecialty choice in academic medical oncology
Abstract: 11013

SCCA Author: Nancy Davidson, MD, President and Executive Director

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma
Abstract: 11517

SCCA Author: Michael Wagner, MD

PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.
Abstract: 9003

SCCA Author: Bernardo Goulart, MD

Publication Only

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Abstract: e16050

SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Treatment patterns in pancreatic cancer: Differences between expert and community practitioners
Abstract: e19207

SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers
Abstract: e16771

SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC
Abstract: E19009

SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study
Abstract: e19157

SCCA Author: Sara Javid, MD, Director, Breast Health Clinic

More information about SCCA’s research at ASCO20 Virtual Scientific Program can be found here: https://www.seattlecca.org/asco

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance (SCCA) brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children’s, and UW Medicine — one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattle’s South Lake Union neighborhood, SCCA has eight clinical care sites, including a medical oncology clinic at EvergreenHealth in Kirkland, Washington; medical and radiation oncology clinics at UW Medicine/Northwest Hospital & Medical Center in Seattle, Washington, medical and radiation oncology services at SCCA Peninsula and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.

*NCI – National Cancer Institute

*NCCN — National Comprehensive Cancer Network

Contacts

Karina San Juan-Guyton, ksanjuangu@seattlecca.org or (206) 606-1926

Heather Platisha, hplatisha@seattlecca.org or (415) 676-8030

close